SCM
XLO icon

Sio Capital Management’s Xilio Therapeutics XLO Stock Holding History

Sio Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Hold
152,464
– – 0.24% 49
2026
Q1 		$1.28M Sell
152,464
-3
-0% -$25 0.18% 59
2025
Q4 		$1.37M Buy
+152,467
New +$1.6M 0.22% 54

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sio Capital Management's XLO Position: Q2 2026 in Review

Sio Capital Management held its Xilio Therapeutics (XLO) position steady in Q2 2026 at 152,464 shares worth $1.46M. The position accounts for 0.24% of the portfolio, ranked #49.

Sio Capital Management first reported a position in XLO in Q4 2025 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Sio Capital Management held 152,464 shares of Xilio Therapeutics worth $1.46M as of Q2 2026.
  • Sio Capital Management left its Xilio Therapeutics share count unchanged in Q2 2026.
  • Xilio Therapeutics made up 0.24% of Sio Capital Management's portfolio in Q2 2026, its #49 holding.
  • Sio Capital Management first reported a position in Xilio Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 27 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Sio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.